Skip to main content
Back
INCY logo

Incyte Corporation

Data quality: 100%
INCY
NASDAQ Healthcare Biotechnology
$90.45
▼ $0.33 (-0.36%)
Mkt Cap: 18.00B
Day Range
$90.00 $92.33
52-Week Range
$53.56 $112.29
Volume
1,332,929
50D / 200D Avg
$100.52 / $89.67
Prev Close
$90.78

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 14.0 0.4
P/B 3.5 2.9
ROE % 29.9 3.8
Net Margin % 25.0 3.9
Rev Growth 5Y % 14.6 10.0
D/E 0.0 0.2

Analyst Price Target

Hold
$108.90 +20.4%
Low: $84.00 High: $135.00
Forward P/E
12.1
Forward EPS
$7.50
EPS Growth (est.)
+0.0%
Est. Revenue
5.6 B

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $4.03
$3.79 – $4.69
 4.7 B 4
FY2029 $3.52
$3.31 – $4.09
 4.6 B 4
FY2028 $9.60
$6.20 – $12.73
 6.5 B 11

Key Takeaways

Revenue grew 14.55% annually over 5 years — strong growth
Earnings grew 3844.96% over the past year
ROE of 29.87% indicates high profitability
Net margin of 25.03% shows strong profitability
Debt/Equity of 0.01 — conservative balance sheet
Generating 1.35B in free cash flow

Growth

Revenue Growth (5Y)
14.55%
Revenue (1Y)21.22%
Earnings (1Y)3844.96%
FCF Growth (3Y)73.69%

Quality

Return on Equity
29.87%
ROIC19.23%
Net Margin25.03%
Op. Margin26.12%

Safety

Debt / Equity
0.01
Current Ratio3.32
Interest Coverage553.03

Valuation

P/E Ratio
13.99
P/B Ratio3.48
EV/EBITDA11.15
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 21.22% Revenue Growth (3Y) 17.95%
Earnings Growth (1Y) 3844.96% Earnings Growth (3Y) 46.73%
Revenue Growth (5Y) 14.55% Earnings Growth (5Y) 7.92%
Profitability
Revenue (TTM) 5.14B Net Income (TTM) 1.29B
ROE 29.87% ROA 18.49%
Gross Margin 91.47% Operating Margin 26.12%
Net Margin 25.03% Free Cash Flow (TTM) 1.35B
ROIC 19.23% FCF Growth (3Y) 73.69%
Safety
Debt / Equity 0.01 Current Ratio 3.32
Interest Coverage 553.03 Dividend Yield 0.00%
Valuation
P/E Ratio 13.99 P/B Ratio 3.48
P/S Ratio 3.50 PEG Ratio 0.00
EV/EBITDA 11.15 Dividend Yield 0.00%
Market Cap 18.00B Enterprise Value 14.97B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 5.14B 4.24B 3.70B 3.39B 2.99B
Net Income 1.29B 32.62M 597.60M 340.66M 948.58M
EPS (Diluted) 6.41 0.15 2.65 1.52 4.27
Gross Profit 4.70B 3.86B 3.38B 3.14B 2.80B
Operating Income 1.34B 80.14M 651.77M 599.56M 637.54M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 6.96B 5.44B 6.78B 5.84B 4.93B
Total Liabilities 1.80B 2.00B 1.59B 1.47B 1.16B
Shareholders' Equity 5.17B 3.45B 5.19B 4.37B 3.77B
Total Debt 69.43M 43.54M 38.29M 41.46M 44.82M
Cash & Equivalents 3.10B 1.69B 3.21B 2.95B 2.06B
Current Assets 5.02B 3.24B 4.65B 4.09B 3.12B
Current Liabilities 1.52B 1.64B 1.24B 1.16B 854.31M

Strategy Scores

This stock passed the criteria for 7 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#876 of 1024
26
Custom Capital Light Compounder
#146 of 213
32
Growth + Value Growth at a Reasonable Price (Peter Lynch)
#170 of 326
50
Growth Growth Investing (Philip Fisher)
#121 of 154
39
Value Value Investing (Warren Buffett)
#78 of 195
46
Custom Balanced Risk
#144 of 148
25
Custom Lower Risk
#115 of 136
35

Recent Activity

Entered Cash Flow Compounder
Mar 24, 2026
Entered Capital Light Compounder
Mar 24, 2026
Entered Growth Investing (Philip Fisher)
Mar 24, 2026
Entered Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026
Entered Value Investing (Warren Buffett)
Mar 24, 2026
Entered Balanced Risk
Mar 24, 2026
Entered Lower Risk
Mar 24, 2026